MOG antibody-associated optic neuritis.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
19
01
2024
accepted:
19
04
2024
revised:
04
04
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder, distinct from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). MOGAD most frequently presents with optic neuritis (MOG-ON), often with characteristic clinical and radiological features. Bilateral involvement, disc swelling clinically and radiologically, and longitudinally extensive optic nerve hyperintensity with associated optic perineuritis on MRI are key characteristics that can help distinguish MOG-ON from optic neuritis due to other aetiologies. The detection of serum MOG immunoglobulin G utilising a live cell-based assay in a patient with a compatible clinical phenotype is highly specific for the diagnosis of MOGAD. This review will highlight the key clinical and radiological features which expedite diagnosis, as well as ancillary investigations such as visual fields, visual evoked potentials and cerebrospinal fluid analysis, which may be less discriminatory. Optical coherence tomography can identify optic nerve swelling acutely, and atrophy chronically, and may transpire to have utility as a diagnostic and prognostic biomarker. MOG-ON appears to be largely responsive to corticosteroids, which are often the mainstay of acute management. However, relapses are common in patients in whom follow-up is prolonged, often in the context of early or rapid corticosteroid tapering. Establishing optimal acute therapy, the role of maintenance steroid-sparing immunotherapy for long-term relapse prevention, and identifying predictors of relapsing disease remain key research priorities in MOG-ON. 摘要: 髓鞘少突胶质细胞糖蛋白 (MOG)抗体相关疾病(MOGAD)是一种脱髓鞘疾病, 有别于多发性硬化症 (MS) 和视神经脊髓炎视神经疾病 (NMOSD) 。MOGAD最常表现为视神经炎 (MOG-ON), 通常具有特征性的临床和影像学特征。MOGAD双侧受累、临床和影像学表现为视盘肿胀以及纵向MRI上广泛视神经高信号伴相关视神经束膜炎是有助于区分MOG-ON与其他病因所致视神经炎的关键特征。在具有相同临床表型的患者中, 利用基于活细胞的测定法检测血清MOG免疫球蛋白G对于MOGAD的诊断具有高度特异性。本综述将重点介绍加快诊断的关键临床和影像学特征及辅助检查, 如视野, 视觉诱发电位和脑脊液分析。这些辅助检查的诊断价值相对较弱, OCT可以识别急性视神经肿胀和慢性视神经萎缩, 并可能作为诊断和预后的生物标志物。MOG-ON似乎对皮质类固醇较敏感, 皮质类固醇通常是急性期治疗的一线药物。然而, 在随访时间延长的患者中很容易复发, 通常是在早期或快速减少皮质类固醇的情况下。最佳策略的的急性期治疗, 维持类固醇保留免疫疗法在长期预防复发中的作用, 以及确定疾病复发的预测因子仍然是MOG-ON的关键研究重点。.
Autres résumés
Type: Publisher
(chi)
摘要: 髓鞘少突胶质细胞糖蛋白 (MOG)抗体相关疾病(MOGAD)是一种脱髓鞘疾病, 有别于多发性硬化症 (MS) 和视神经脊髓炎视神经疾病 (NMOSD) 。MOGAD最常表现为视神经炎 (MOG-ON), 通常具有特征性的临床和影像学特征。MOGAD双侧受累、临床和影像学表现为视盘肿胀以及纵向MRI上广泛视神经高信号伴相关视神经束膜炎是有助于区分MOG-ON与其他病因所致视神经炎的关键特征。在具有相同临床表型的患者中, 利用基于活细胞的测定法检测血清MOG免疫球蛋白G对于MOGAD的诊断具有高度特异性。本综述将重点介绍加快诊断的关键临床和影像学特征及辅助检查, 如视野, 视觉诱发电位和脑脊液分析。这些辅助检查的诊断价值相对较弱, OCT可以识别急性视神经肿胀和慢性视神经萎缩, 并可能作为诊断和预后的生物标志物。MOG-ON似乎对皮质类固醇较敏感, 皮质类固醇通常是急性期治疗的一线药物。然而, 在随访时间延长的患者中很容易复发, 通常是在早期或快速减少皮质类固醇的情况下。最佳策略的的急性期治疗, 维持类固醇保留免疫疗法在长期预防复发中的作用, 以及确定疾病复发的预测因子仍然是MOG-ON的关键研究重点。.
Identifiants
pubmed: 38783085
doi: 10.1038/s41433-024-03108-y
pii: 10.1038/s41433-024-03108-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22:268–82.
pubmed: 36706773
doi: 10.1016/S1474-4422(22)00431-8
Linnington C, Webb M, Woodhams PL. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol. 1984;6:387–96.
pubmed: 6207204
doi: 10.1016/0165-5728(84)90064-X
de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26:806–14.
pubmed: 31094288
doi: 10.1177/1352458519845112
O’Connell K, Hamilton-Shield A, Woodhall M, Messina S, Mariano R, Waters P, et al. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020;91:1126–8.
pubmed: 32576617
doi: 10.1136/jnnp-2020-323158
Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol. 2023;14:1260358.
pubmed: 37789888
pmcid: 10542411
doi: 10.3389/fneur.2023.1260358
Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128–38.
pubmed: 29136091
doi: 10.1093/brain/awx276
Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89:127–37.
pubmed: 29142145
doi: 10.1136/jnnp-2017-316880
Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA, et al. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol. 2020;77:82–93.
pubmed: 31545352
doi: 10.1001/jamaneurol.2019.2940
Santoro JD, Beukelman T, Hemingway C, Hokkanen SRK, Tennigkeit F, Chitnis T. Attack phenotypes and disease course in pediatric MOGAD. Ann Clin Transl Neurol. 2023;10:672–85.
pubmed: 37000895
pmcid: 10187731
doi: 10.1002/acn3.51759
Gaertner S, de Graaf KL, Greve B, Weissert R. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology. 2004;63:2381–3.
pubmed: 15623705
doi: 10.1212/01.WNL.0000147259.34163.33
Kuhle J, Lindberg RL, Regeniter A, Mehling M, Hoffmann F, Reindl M, et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol. 2007;254:160–8.
pubmed: 17334662
doi: 10.1007/s00415-006-0299-4
Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349:139–45.
pubmed: 12853586
doi: 10.1056/NEJMoa022328
Rauer S, Euler B, Reindl M, Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry. 2006;77:739–42.
pubmed: 16705196
pmcid: 2077442
doi: 10.1136/jnnp.2005.077784
Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci USA. 2003;100:9446–51.
pubmed: 12874380
pmcid: 170938
doi: 10.1073/pnas.1133443100
de Graaf KL, Albert M, Weissert R. Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity. J Biol Chem. 2012;287:17206–13.
pubmed: 22493449
pmcid: 3366859
doi: 10.1074/jbc.M111.304246
Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15:307–24.
pubmed: 26708342
doi: 10.1016/j.autrev.2015.12.004
O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13:211–7.
pubmed: 17237795
pmcid: 3429369
doi: 10.1038/nm1488
McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009;183:4067–76.
pubmed: 19687098
doi: 10.4049/jimmunol.0801888
Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009;66:833–42.
pubmed: 20033986
doi: 10.1002/ana.21916
Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79:1273–7.
pubmed: 22914827
doi: 10.1212/WNL.0b013e31826aac4e
Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474–81.
pubmed: 24415568
pmcid: 3937859
doi: 10.1212/WNL.0000000000000101
Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014;1:e40.
pubmed: 25364774
pmcid: 4215392
doi: 10.1212/NXI.0000000000000040
Höftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139:875–92.
pubmed: 32048003
pmcid: 7181560
doi: 10.1007/s00401-020-02132-y
Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143:1431–46.
pubmed: 32412053
doi: 10.1093/brain/awaa102
Kothur K, Wienholt L, Tantsis EM, Earl J, Bandodkar S, Prelog K, et al. B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination. PLoS One. 2016;11:e0149411.
pubmed: 26919719
pmcid: 4769285
doi: 10.1371/journal.pone.0149411
Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord. 2021;48:102696.
pubmed: 33360264
doi: 10.1016/j.msard.2020.102696
Winklmeier S, Schlüter M, Spadaro M, Thaler FS, Vural A, Gerhards R, et al. Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2019;6:625.
pubmed: 31611268
pmcid: 6857907
doi: 10.1212/NXI.0000000000000625
Li X, Wang L, Zhou L, ZhangBao J, Miao MZ, Lu C, et al. The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination. Mult Scler Relat Disord. 2019;36:101397.
pubmed: 31546225
doi: 10.1016/j.msard.2019.101397
Hofer LS, Ramberger M, Gredler V, Pescoller AS, Rostásy K, Sospedra M, et al. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. Front Immunol. 2020;11:1188.
pubmed: 32625206
pmcid: 7311656
doi: 10.3389/fimmu.2020.01188
Spadaro M, Winklmeier S, Beltrán E, Macrini C, Höftberger R, Schuh E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018;84:315–28.
pubmed: 30014603
doi: 10.1002/ana.25291
Keller CW, Lopez JA, Wendel E-M, Ramanathan S, Gross CC, Klotz L, et al. Complement Activation Is a Prominent Feature of MOGAD. Ann Neurol. 2021;90:976–82.
pubmed: 34569094
doi: 10.1002/ana.26226
Mader S, Ho S, Wong HK, Baier S, Winklmeier S, Riemer C, et al. Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci USA. 2023;120:e2300648120.
pubmed: 36943883
pmcid: 10068779
doi: 10.1073/pnas.2300648120
Ramanathan S, Brilot F, Irani SR, Dale RC. Origins and immunopathogenesis of autoimmune central nervous system disorders. Nat Rev Neurol. 2023;19:172–90.
pubmed: 36788293
doi: 10.1038/s41582-023-00776-4
Jeyakumar N, Waller S, Mahant N, Ramanathan S, Henderson APD. A case of CSF anti-MOG antibody-positive papillitis with intermediate uveitis in the setting of acute neurosyphilis. Neuroimmunol Rep. 2021;1:100033.
doi: 10.1016/j.nerep.2021.100033
Rusescu B-V, Diederich NJ, Tsobo C, Marignier R, Kerschen P. MOG antibody-associated optic neuritis in the setting of acute CMV infection. J Neurological Sci. 2017;382:44–6.
doi: 10.1016/j.jns.2017.09.011
Mutete F, Mwendaweli N, Asukile M. mulubwa s, Mumbi W, Saylor D. MOG Antibody-Associated Bilateral Optic Neuritis Associated with Johnson and Johnson COVID-19 Vaccination (P12-3.009). Neurology. 2023;100:2691.
doi: 10.1212/WNL.0000000000202726
Molazadeh N, Bose G, Lotan I, Levy M. Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review. Mult Scler J Exp Transl Clin. 2022;8:20552173221128170.
pubmed: 36311694
pmcid: 9597055
Redenbaugh V, Flanagan EP, Floris V, Zara P, Bhatti MT, Sanchez F, et al. Exposure to TNF inhibitors is rare at MOGAD presentation. J Neurol Sci. 2022;432:120044.
pubmed: 34728073
doi: 10.1016/j.jns.2021.120044
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.
pubmed: 25613900
doi: 10.1126/science.1260419
Boccuni I, Bas-Orth C, Bruehl C, Draguhn A, Fairless R. Glutamate transporter contribution to retinal ganglion cell vulnerability in a rat model of multiple sclerosis. Neurobiol Dis. 2023;187:106306.
pubmed: 37734623
doi: 10.1016/j.nbd.2023.106306
Hofman P, Hoyng P, vanderWerf F, Vrensen GF, Schlingemann RO. Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Invest Ophthalmol Vis Sci. 2001;42:895–901.
pubmed: 11274064
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.
pubmed: 27793206
pmcid: 5086042
doi: 10.1186/s12974-016-0718-0
Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018;195:8–15.
pubmed: 30055153
pmcid: 6371779
doi: 10.1016/j.ajo.2018.07.020
Rempe T, Tarhan B, Rodriguez E, Viswanathan VT, Gyang TV, Carlson A, et al. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience. Mult Scler Relat Disord. 2021;48:102718.
pubmed: 33388560
doi: 10.1016/j.msard.2020.102718
Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson APD, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler J. 2015;22:470–82.
doi: 10.1177/1352458515593406
Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22:89–100.
pubmed: 36155661
doi: 10.1016/S1474-4422(22)00187-9
Shor N, Aboab J, Maillart E, Lecler A, Bensa C, Le Guern G, et al. Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. Eur J Neurol. 2020;27:384–91.
pubmed: 31532865
doi: 10.1111/ene.14089
Narongkhananukul C, Padungkiatsagul T, Jindahra P, Khongkhatithum C, Thampratankul L, Vanikieti K. MOG-IgG- versus AQP4-IgG-Positive Optic Neuritis in Thailand: Clinical Characteristics and Long-Term Visual Outcomes Comparison. Clin Ophthalmol. 2020;14:4079–88.
pubmed: 33273804
pmcid: 7705275
doi: 10.2147/OPTH.S288224
Ducloyer JB, Caignard A, Aidaoui R, Ollivier Y, Plubeau G, Santos-Moskalyk S, et al. MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis. Br J Ophthalmol. 2020;104:842–5.
pubmed: 31582363
doi: 10.1136/bjophthalmol-2019-314845
Kang H, Qiu H, Hu X, Wei S, Tao Y. Differences in Neuropathic Pain and Radiological Features Between AQP4-ON, MOG-ON, and IDON. Front Pain Res. 2022;3:870211.
doi: 10.3389/fpain.2022.870211
Ambika S, Durgapriyadarshini S, Padmalakshmi K, Noronha V, Arjundas D. Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica. Indian J Ophthalmol. 2022;70:194–200.
pubmed: 34937238
doi: 10.4103/ijo.IJO_887_21
Dauby S, Dive D, Lutteri L, Andris C, Hansen I, Maquet P, et al. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Acta Neurol Belg. 2022;122:135–44.
pubmed: 34097296
doi: 10.1007/s13760-021-01712-3
Lotan I, Brody J, Hellmann MA, Bialer O, Ganelin-Cohen E, Michaeli N, et al. Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. J Neurol. 2018;265:1985–8.
pubmed: 29938337
doi: 10.1007/s00415-018-8956-y
Narayan RN, Wang C, Sguigna P, Husari K, Greenberg B. Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations. Mult Scler Relat Disord. 2019;27:30–3.
pubmed: 30300850
doi: 10.1016/j.msard.2018.10.003
Wong WK, Troedson C, Peacock K, Brilot-Turville F, Menezes MP, Dale RC, et al. Steroid-responsive aseptic meningitis with raised intracranial pressure syndrome associated with myelin oligodendrocyte glycoprotein autoantibodies. J Paediatr Child Health. 2022;58:2322–6.
pubmed: 36000565
pmcid: 10087128
doi: 10.1111/jpc.16189
Murtagh P, Coman A, Stephenson K, Gaughan M, Ryan D, McNeill G, et al. Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathies. Int J Ophthalmol. 2022;15:1095–107.
pubmed: 35919317
pmcid: 9318083
doi: 10.18240/ijo.2022.07.09
Chen JJ, Flanagan EP, Bhatti MT, Tisavipat N, Jamali S, Kunchok A, et al. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord. 2022;68:104237.
pubmed: 36252317
doi: 10.1016/j.msard.2022.104237
Vicini R, Brügger D, Abegg M, Salmen A, Grabe HM. Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis. J Neurol. 2021;268:276–84.
pubmed: 32785840
doi: 10.1007/s00415-020-10097-x
Fazzone HE, Lefton DR, Kupersmith MJ. Optic neuritis: correlation of pain and magnetic resonance imaging. Ophthalmology. 2003;110:1646–9.
pubmed: 12917187
doi: 10.1016/S0161-6420(03)00477-9
Jang Y, Kim SM, Yun YI, Lee HJ, Kim SJ, Jung JH, et al. Comparison between optic neuritis associated with antibody against myelin oligodendrocyte glycoprotein and presumed idiopathic optic perineuritis. Neurol Sci. 2020;41:2755–60.
pubmed: 32277391
doi: 10.1007/s10072-020-04371-z
Asseyer S, Hamblin J, Messina S, Mariano R, Siebert N, Everett R, et al. Prodromal headache in MOG-antibody positive optic neuritis. Mult Scler Relat Disord. 2020;40:101965.
pubmed: 32062443
doi: 10.1016/j.msard.2020.101965
Zhao Y, Tan S, Chan TCY, Xu Q, Zhao J, Teng D, et al. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102:1372–7.
pubmed: 29363529
doi: 10.1136/bjophthalmol-2017-311177
Ramanathan S, Fraser C, Curnow SR, Ghaly M, Leventer RJ, Lechner-Scott J, et al. Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. Eur J Neurol. 2019;26:1137–e75.
pubmed: 30748058
doi: 10.1111/ene.13932
Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, et al. Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. Neuroophthalmology. 2020;44:1–4.
pubmed: 32076441
doi: 10.1080/01658107.2019.1607883
Gupta P, Goyal V, Srivastava AK, Pandit AK, Prasad K. Uveitis, optic neuritis and MOG. Mult Scler J Exp Transl Clin. 2020;6:2055217320925107.
pubmed: 32489673
pmcid: 7238848
Deschamps R, Vasseur V, Shor N, Vignal C, Salomon L, Gout O, et al. A new association: acute macular neuroretinopathy in acute optic neuritis. Acta Ophthalmologica. 2019;97:e753–e6.
pubmed: 30761755
pmcid: 6798266
doi: 10.1111/aos.14054
Kon T, Hikichi H, Ueno T, Suzuki C, Nunomura J, Kaneko K, et al. Myelin Oligodendrocyte Glycoprotein-IgG-positive Recurrent Bilateral Optic Papillitis with Serous Retinal Detachment. Intern Med. 2018;57:3307–12.
pubmed: 29780155
pmcid: 6287979
doi: 10.2169/internalmedicine.9840-17
Mittal A, Baig IF, Merchant AG, Chen JJ, Choi JJ, Goldberg A, et al. Sjögren Disease and Myelin Oligodendrocyte Glycoprotein Antibody–Associated Optic Neuritis. J Neuro Ophthalmol. 2021;41:e48–e50.
Budoff G, Bhagat N, Frohman L. Anti-Myelin Oligodendrocyte Glycoprotein Optic Neuritis Presenting with Dense Premacular Hemorrhage. Ophthalmology. 2019;126:1639.
pubmed: 31759500
doi: 10.1016/j.ophtha.2019.07.004
Wagley S, Wang Y, McClelland CM, Chen JJ, Lee MS. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis Presenting as Idiopathic Orbital Inflammatory Syndrome. J Neuro Ophthalmol. 2021;41:e46–e47.
Kurathong S, Sanpatchayapong A, Apiwattanakul M. Case Report: Anti-myelin Oligodendrocyte Glycoprotein (MOG) Positive in a Patient Presented with Orbital Apex Syndrome. Neuroophthalmology. 2019;44:255–7.
pubmed: 33012911
pmcid: 7518306
doi: 10.1080/01658107.2019.1571089
Valérie B, Claudine T, Etienne B-M, Etienne R. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology. 1999;52:179.
doi: 10.1212/WNL.52.1.179
Shugaiv E, Tüzün E, Kürtüncü M, Kıyat-Atamer A, Çoban A, Akman-Demir G, et al. Uveitis as a prognostic factor in multiple sclerosis. Mult Scler. 2015;21:105–7.
pubmed: 24948689
doi: 10.1177/1352458514539782
Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. JAMA Neurol. 2018;75:478–87.
pubmed: 29305608
pmcid: 5885190
doi: 10.1001/jamaneurol.2017.4601
Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. Ann Neurol. 2021;89:30–41.
pubmed: 32959427
doi: 10.1002/ana.25909
Parrotta E, Kister I. The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults. Front Neurol. 2020;11:960.
pubmed: 33013639
pmcid: 7509044
doi: 10.3389/fneur.2020.00960
Winter A, Chwalisz B. MRI Characteristics of NMO, MOG and MS Related Optic Neuritis. Semin Ophthalmol. 2020;35:333–42.
pubmed: 33395326
doi: 10.1080/08820538.2020.1866027
Rizzo JF, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109:1679–84.
pubmed: 12208717
doi: 10.1016/S0161-6420(02)01148-X
Salama S, Khan M, Levy M, Izbudak I. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult Scler Relat Disord. 2019;29:15–22.
pubmed: 30658259
pmcid: 6431795
doi: 10.1016/j.msard.2019.01.021
Carandini T, Sacchi L, Bovis F, Azzimonti M, Bozzali M, Galimberti D, et al. Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021;54:103118.
pubmed: 34246019
doi: 10.1016/j.msard.2021.103118
Tajfirouz D, Padungkiatsagul T, Beres S, Moss HE, Pittock S, Flanagan E, et al. Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder. Mult Scler. 2022;28:149–53.
pubmed: 33975499
doi: 10.1177/13524585211011450
Chen C, Liu C, Fang L, Zou Y, Ruan H, Wang Y, et al. Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study. J Neurol Sci. 2019;405:116430.
pubmed: 31465985
doi: 10.1016/j.jns.2019.116430
Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020;26:1854–65.
pubmed: 31937191
pmcid: 7363520
doi: 10.1177/1352458519893093
Purvin V, Kawasaki A, Jacobson DM. Optic perineuritis: clinical and radiographic features. Arch Ophthalmol. 2001;119:1299–306.
pubmed: 11545635
doi: 10.1001/archopht.119.9.1299
Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflammation. 2015;2:e163-e.
doi: 10.1212/NXI.0000000000000163
Yanagidaira M, Hattori T, Emoto H, Kiyosawa M, Yokota T. Optic perineuritis with anti-myelin oligodendrocyte glycoprotein antibody. Mult Scler Relat Disord. 2020;38:101444.
pubmed: 31711001
doi: 10.1016/j.msard.2019.101444
Xie JS, Donaldson L, Margolin E. Optic perineuritis: A Canadian case series and literature review. J Neurol Sci. 2021;430:120035.
pubmed: 34717266
doi: 10.1016/j.jns.2021.120035
Sulaiman FN, Kamardin NF, Sultan Abdul Kader MI, Ch’ng H, Wan Abdul Halim WH. Myelin Oligodendrocyte Glycoprotein Optic Neuritis Presenting With Orbital Apex Syndrome. Cureus. 2023;15:e38975.
pubmed: 37313108
pmcid: 10259875
Matsuda R, Kezuka T, Umazume A, Okunuki Y, Goto H, Tanaka K. Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. Neuro Ophthalmol. 2015;39:213–9.
doi: 10.3109/01658107.2015.1072726
Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, et al. Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. PloS One. 2017;12:e0170847-e.
doi: 10.1371/journal.pone.0170847
Chen JJ, Sotirchos ES, Henderson AD, Vasileiou ES, Flanagan EP, Bhatti MT, et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Mult Scler Relat Disord. 2022;58:103525.
pubmed: 35038647
pmcid: 8882134
doi: 10.1016/j.msard.2022.103525
Filippatou AG, Mukharesh L, Saidha S, Calabresi PA, Sotirchos ES. AQP4-IgG and MOG-IgG Related Optic Neuritis—Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:540156.
pubmed: 33132999
pmcid: 7578376
doi: 10.3389/fneur.2020.540156
Barnes S, You Y, Shen T, Hardy TA, Fraser C, Reddel SW, et al. Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis. Mult Scler J Exp Transl Clin. 2021;7:20552173211063126.
pubmed: 35035987
pmcid: 8753081
Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282.
pubmed: 27802824
pmcid: 5088645
doi: 10.1186/s12974-016-0720-6
Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, et al. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD. J Neurol Sci. 2022;437:120269.
pubmed: 35483239
doi: 10.1016/j.jns.2022.120269
Costello F. Optical Coherence Tomography in Neuro-ophthalmology. Neurol Clin. 2017;35:153–63.
pubmed: 27886892
doi: 10.1016/j.ncl.2016.08.012
Deschamps R, Philibert M, Lamirel C, Lambert J, Vasseur V, Gueguen A, et al. Visual field loss and structure-function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody. Mult Scler. 2021;27:855–63.
pubmed: 32633601
doi: 10.1177/1352458520937281
Yu J, Huang Y, Zhou L, ZhangBao J, Zong Y, Quan C, et al. Comparison of the retinal vascular network and structure in patients with optic neuritis associated with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies: an optical coherence tomography angiography study. J Neurol. 2021;268:4874–81.
pubmed: 34086096
doi: 10.1007/s00415-021-10609-3
Yao Y, Li X, Xu Y, Liang X, Yang L, Shi FD, et al. The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON. BMC Neurol. 2022;22:323.
pubmed: 36030231
pmcid: 9419345
doi: 10.1186/s12883-022-02848-2
Yu J, Huang Y, Quan C, Zhou L, ZhangBao J, Wu K, et al. Alterations in the Retinal Vascular Network and Structure in MOG Antibody-Associated Disease: An Optical Coherence Tomography Angiography Study. J Neuroophthalmol. 2021;41:e424–e32.
pubmed: 33136671
doi: 10.1097/WNO.0000000000001116
Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hummert MW, Ringelstein M, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation. 2020;17:261.
pubmed: 32883348
pmcid: 7470615
doi: 10.1186/s12974-020-01824-2
Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflammation. 2020;7:e674-e.
doi: 10.1212/NXI.0000000000000674
Tea F, Lopez JA, Ramanathan S, Merheb V, Lee FXZ, Zou A, et al. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Commun. 2019;7:145.
doi: 10.1186/s40478-019-0786-3
Lopez JA, Houston SD, Tea F, Merheb V, Lee FXZ, Smith S, et al. Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. J Appl Lab Med. 2022;7:12–25.
pubmed: 34718586
doi: 10.1093/jalm/jfab101
Kwon YN, Kim B, Kim JS, Mo H, Choi K, Oh SI, et al. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1095.
Pace S, Orrell M, Woodhall M, Palace J, Leite MI, Irani SR, et al. Frequency of MOG-IgG in cerebrospinal fluid versus serum. J Neurol Neurosurg Psychiatry. 2022;93:334–5.
pubmed: 34261747
doi: 10.1136/jnnp-2021-326779
Dale RC, Ramanathan S. Clinical decision making in MOG antibody-associated disease. Lancet Neurol. 2021;20:695–7.
pubmed: 34418387
doi: 10.1016/S1474-4422(21)00247-7
Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Namatame C, Kuroda H, et al. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. Brain. 2023;146:3938–48.
pubmed: 37061817
doi: 10.1093/brain/awad122
Carta S, Cobo Calvo Á, Armangué T, Saiz A, Lechner C, Rostásy K, et al. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study. Neurology. 2023;100:e1095–e108.
pubmed: 36526426
pmcid: 10074465
doi: 10.1212/WNL.0000000000201662
Petzold A, Fraser CL, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21:1120–34.
pubmed: 36179757
doi: 10.1016/S1474-4422(22)00200-9
Greco G, Colombo E, Gastaldi M, Ahmad L, Tavazzi E, Bergamaschi R, et al. Beyond Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies: Alternative Causes of Optic Neuritis. Int J Mol Sci. 2023;24:15986.
pubmed: 37958968
pmcid: 10649355
doi: 10.3390/ijms242115986
Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. JAMA Neurol. 2016;73:1297–307.
pubmed: 27618707
doi: 10.1001/jamaneurol.2016.2549
Chen JJ, Aksamit AJ, McKeon A, Pittock SJ, Weinshenker BG, Leavitt JA, et al. Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody–Positive Meningoencephalitis. J Neuro Ophthalmol. 2018;38:276–81.
Wang S, Hou H, Tang Y, Zhang S, Wang G, Guo Z, et al. An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes. Neural Regen Res. 2023;18:2357–64.
Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54:38–50.
pubmed: 12838519
doi: 10.1002/ana.10587
Kaushik M, Virdee J, Giridharan S, Chavda SV, Batra R. Response of Recoverin-Positive Optic Neuritis to Chemotherapy, Steroid, and Plasma Exchange. Journal of neuro-ophthalmology. 2024;44:e79–e81.
Erdağ E, Emekli AS, Gündüz T, Küçükali Cİ, Kürtüncü M, Tüzün E. Serum IgG of patients with relapsing inflammatory optic neuropathy immunoreacts with Sox2-positive glial cells of the optic nerve. Mult Scler Relat Disord. 2023;73:104694.
pubmed: 37023542
doi: 10.1016/j.msard.2023.104694
Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137:2178–92.
pubmed: 24951641
pmcid: 4107739
doi: 10.1093/brain/awu142
Desmond PK, Ben JB, Elizabeth MG, Gordon TP. Optic neuropathy associated with systemic sarcoidosis. Neurol Neuroimmunol Neuroinflammation. 2016;3:e270.
doi: 10.1212/NXI.0000000000000270
Kidd D, Beynon HL. The neurological complications of systemic sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis. 2003;20:85–94.
Asgari N, Jarius S, Laustrup H, Skejoe HPB, Lillevang ST, Weinshenker BG, et al. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. Mult Scler. 2018;24:331–9.
pubmed: 28326889
doi: 10.1177/1352458517699791
Kahloun R, Abroug N, Ksiaa I, Mahmoud A, Zeghidi H, Zaouali S, et al. Infectious optic neuropathies: a clinical update. Eye Brain. 2015;7:59–81.
pubmed: 28539795
pmcid: 5398737
Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber’s hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol. 1991;111:750–62.
pubmed: 2039048
doi: 10.1016/S0002-9394(14)76784-4
Raviskanthan S, Perera N, Fok A. Recurrent Bilateral Myelin Oligodendrocyte Glycoprotein Antibody Optic Neuritis in a Leber Hereditary Optic Neuropathy Carrier. J Neuro Ophthalmol. 2020;40:246–7.
doi: 10.1097/WNO.0000000000000853
Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003;126:276–84.
pubmed: 12538397
doi: 10.1093/brain/awg045
Petzold A, Woodhall M, Khaleeli Z, Tobin WO, Pittock SJ, Weinshenker BG, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. J Neurol Neurosurg Psychiatry. 2019;90:1021–6.
pubmed: 31118222
doi: 10.1136/jnnp-2019-320493
Lee H-J, Kim B, Waters P, Woodhall M, Irani S, Ahn S, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation. 2018;15:302.
pubmed: 30382857
pmcid: 6208174
doi: 10.1186/s12974-018-1335-x
Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010;81:109–11.
pubmed: 20019228
doi: 10.1136/jnnp.2008.146894
Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study. JAMA Neurol. 2014;71:276–83.
pubmed: 24425068
doi: 10.1001/jamaneurol.2013.5857
Oliveira LM, Apóstolos-Pereira SL, Pitombeira MS, Bruel Torretta PH, Callegaro D, Sato DK. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler. 2019;25:1907–14.
pubmed: 30417715
doi: 10.1177/1352458518811597
Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, et al. Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom. JAMA Netw Open. 2022;5:e2142780-e.
doi: 10.1001/jamanetworkopen.2021.42780
Wendel EM, Thonke HS, Bertolini A, Baumann M, Blaschek A, Merkenschlager A, et al. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome. Neurol Neuroimmunol Neuroinflammation. 2022;9:e200035.
doi: 10.1212/NXI.0000000000200035
Budhram A, Kunchok A, Flanagan E. Adding FUEL to the FLAMES: FLAIR-variable Unilateral Enhancement of the Leptomeninges (FUEL) in MOG-IgG-Associated Disease (862). Neurology. 2020;94:862. 15_supplement
doi: 10.1212/WNL.94.15_supplement.862
Wong YYM, Hacohen Y, Armangue T, Wassmer E, Verhelst H, Hemingway C, et al. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol. 2018;25:782–6.
pubmed: 29443442
doi: 10.1111/ene.13602
Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, Boon M, van Dijk KG, Eikelenboom MJ, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol. 2012;259:1929–35.
pubmed: 22349866
pmcid: 3432787
doi: 10.1007/s00415-012-6441-6
Chen B, Gomez-Figueroa E, Redenbaugh V, Francis A, Satukijchai C, Wu Y, et al. Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD? Ann Neurol. 2023;94:508–17.
pubmed: 37394961
doi: 10.1002/ana.26731
Cobo-Calvo Á, Sepúlveda M, Bernard-Valnet R, Ruiz A, Brassat D, Martínez-Yélamos S, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Mult Scler. 2016;22:312–9.
pubmed: 26209592
doi: 10.1177/1352458515591071
Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016;263:1349–60.
pubmed: 27147513
pmcid: 5831396
doi: 10.1007/s00415-016-8147-7
Akaishi T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, et al. Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders. J Neuroimmunol. 2021;351:577467.
pubmed: 33388541
doi: 10.1016/j.jneuroim.2020.577467
Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88:811–7.
pubmed: 28684532
doi: 10.1136/jnnp-2017-315998
Liyanage G, Trewin BP, Lopez JA, Andersen J, Tea F, Merheb V, et al. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024. https://doi.org/10.1136/jnnp-2023-332851 . [Epub ahead of print].
Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chanatre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267:3565–77.
pubmed: 32623595
pmcid: 7954658
doi: 10.1007/s00415-020-10026-y
Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581–8.
pubmed: 1734247
doi: 10.1056/NEJM199202273260901
Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, et al. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. 2018;136:419–22.
pubmed: 29470571
pmcid: 5876803
doi: 10.1001/jamaophthalmol.2017.6757
Nosadini M, Eyre M, Giacomini T, Valeriani M, Della Corte M, Praticò AD, et al. Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200065.
Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflammation. 2019;6:e572.
doi: 10.1212/NXI.0000000000000572
Rode J, Pique J, Maarouf A, Ayrignac X, Bourre B, Ciron J, et al. Time to steroids impacts visual outcome of optic neuritis in MOGAD. J Neurol Neurosurg Psychiatry. 2023;94:309–13.
pubmed: 36600666
doi: 10.1136/jnnp-2022-330360
Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma Clin Immunol. 2013;9:30.
pubmed: 23947590
doi: 10.1186/1710-1492-9-30
Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, et al. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. 2022;79:518–25.
pubmed: 35377395
pmcid: 8981066
doi: 10.1001/jamaneurol.2022.0489
Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251.
pubmed: 32629363
pmcid: 7895306
doi: 10.1016/j.msard.2020.102251
Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, et al. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. Ann Neurol. 2020;87:256.
pubmed: 31725931
doi: 10.1002/ana.25648
Spagni G, Sun B, Monte G, Sechi E, Iorio R, Evoli A, et al. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94:62–9.
pubmed: 36283808
doi: 10.1136/jnnp-2022-330086
Seneviratne SO, Marriott M, Ramanathan S, Yeh W, Brilot-Turville F, Butzkueven H, et al. Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. BMC Neurol. 2022;22:84.
pubmed: 35264149
pmcid: 8905766
doi: 10.1186/s12883-022-02612-6